MDxHealth SA (MDXH)
MDxHealth is a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care.
Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications.
Our unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., Prostate Specific Antigen, digital rectal exam, age) used by clinicians.
Our lead products address men at risk for developing prostate cancer, but in addition, we are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide our clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care.
|IPO Date||Nov 4, 2021|
|Industry||Diagnostics & Research|
CAP Business Center
Herstal, Liege 4040
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Koen Hoffman||Independent Non-Executive Director (Chairperson of the Board of Directors)|
|Michael K. McGarrity||Executive Director (Chief Executive Officer)|
|Rudi Mariën||Non-Executive Director|
|Jan Pensaert||Non-Executive Director|
|Dr. Lieve Verplancke||Independent Non-Executive Director|
|Hilde Windels||Independent Non-Executive Director|
|Dr. Regine Slagmulder||Independent Non-Executive Director|
|Dr. Eric Bednarski||Non-Executive Director|
Latest SEC Filings
|Nov 23, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Nov 15, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Nov 12, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 9, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Nov 5, 2021||424B4||Prospectus [Rule 424(b)(4)]|
|Nov 4, 2021||EFFECT||Notice of Effectiveness|
|Nov 3, 2021||CERT||Certification by an exchange approving securities for listing|
|Nov 1, 2021||8-A12B||Registration of securities [Section 12(b)]|
|Nov 1, 2021||F-1/A||Registration statement for certain foreign private issuers|
|Oct 27, 2021||F-1/A||Registration statement for certain foreign private issuers|
|View All SEC Filings|